Loading organizations...
§ Private Profile · Oakdale, PA, USA
Clinical-stage medical technology company developing sonodynamic therapy using ultrasound for solid tumors, focused on glioblastoma.
Based in Chanhassen, Minnesota, Alpheus Medical is a clinical-stage biotechnology company developing sonodynamic therapy platforms to treat severe solid tumors such as glioblastoma. The company utilizes a proprietary non-invasive device that pairs a tumor-accumulating drug with low-intensity ultrasound to selectively destroy cancer cells while minimizing systemic exposure. Operating with fewer than 50 employees, the enterprise has raised approximately $82 million in total venture capital funding to advance its clinical trials. This financing includes an oversubscribed $52 million Series B round in May 2025 backed by prominent institutional investors such as HealthQuest Capital, Samsara BioCapital, Action Potential Venture Capital, and OrbiMed. Following a 2022 FDA Orphan Drug Designation, the organization is currently initiating Phase 2B randomized clinical trials for its lead neuro-oncology treatment program. Alpheus Medical was originally founded in 2019 by Dr. Vijay Agarwal.
Alpheus Medical has raised $82.0M across 3 funding rounds.
Alpheus Medical has raised $82.0M in total across 3 funding rounds.
Alpheus Medical has raised $82.0M across 3 funding rounds. Most recently, it raised $52.0M Series B in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $52M Series B | Conrad Wang, Samsara BioCapital | Action Potential Venture Capital, Cofounders Capital, OrbiMed, VenBio Partners, Westlake Village BioPartners, Brain Tumor Investment Fund, BrightEdge, Sontag Foundation | Announced |
| Nov 1, 2022 | $14M Series A | — | Action Potential Venture Capital, Vasudev Bailey, Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, OrbiMed, Polaris Partners, RA Capital, Section 32, VenBio Partners, Westlake Village BioPartners, Anne Wojcicki | Announced |
| Nov 1, 2021 | $16M Series A | Action Potential Venture Capital, OrbiMed | Cofounders Capital, VenBio Partners, Westlake Village BioPartners, BrightEdge, National Brain Tumor Society, SV Health Investors | Announced |
Alpheus Medical has raised $82.0M in total across 3 funding rounds.
Alpheus Medical's investors include Conrad Wang, Samsara BioCapital, Action Potential Venture Capital, Cofounders Capital, OrbiMed, venBio, Westlake Village BioPartners, Brain Tumor Investment Fund, BrightEdge, Sontag Foundation, Vasudev Bailey, Asset Management Ventures.
Alpheus Medical is a private, clinical-stage biotechnology company developing sonodynamic therapy (SDT) for aggressive brain cancers, primarily glioblastoma multiforme (GBM).[1][2][3] Its lead product combines low-intensity diffuse ultrasound (LIDU™) delivered via a proprietary non-invasive device with oral 5-aminolevulinic acid (5-ALA), an FDA-approved drug that accumulates in tumor cells, to selectively destroy cancer cells across the entire brain hemisphere while sparing healthy tissue.[1][2][4] This outpatient treatment addresses GBM's infiltrative nature, targeting visible and invisible tumor cells without imaging, sedation, or surgery, serving patients with newly diagnosed or recurrent high-grade gliomas who lack better options.[2][4][5] Positive Phase 1/2 trial results showed strong safety, extended median overall survival and progression-free survival versus historical data, and early efficacy in non-resectable cases, with a randomized control trial planned for newly diagnosed GBM.[4][5]
Founded in 2014 in Chanhassen, Minnesota, Alpheus Medical (formerly CranioVation) emerged to tackle the unmet need in GBM treatment, where tumors infiltrate beyond surgical reach despite resections.[1][2] Led by Founder, President, and CEO (name not specified in available data), the leadership includes a Chief Financial Officer, Chief Technology Officer, Vice President of Clinical Operations, Vice President of Chemistry, Manufacturing & Controls, and Vice President of Research & Development.[3] The idea stemmed from sonodynamic therapy's potential to activate drugs with ultrasound non-invasively, building early traction through collaborations with neuro-oncology leaders and investors like HealthQuest Capital, Brightedge (American Cancer Society's venture arm), and the Brain Tumor Investment Fund (National Brain Tumor Society subsidiary).[1][4][5] Pivotal moments include positive Phase 1/2 results presented at the 2024 Society of Neuro-Oncology meeting and a 2025 Journal of Neuro-Oncology publication on single-dose efficacy in non-resectable GBM.[4][5]
Alpheus rides the wave of sonodynamic therapy (SDT), a paradigm shift from invasive brain cancer treatments amid rising demand for precision, non-thermal oncology tools.[2][5] Timing aligns with GBM's dismal prognosis—median survival under 15 months post-diagnosis—and failures of focal therapies against diffuse infiltration, amplified by advances in ultrasound tech and FDA-approved sensitizers like 5-ALA.[1][2] Market forces favor it: aging populations boost brain tumor incidence, while investors target "investigational" breakthroughs supported by nonprofits like the American Cancer Society, filling gaps in high-grade glioma care.[1][4][5] Alpheus influences the ecosystem by validating SDT for solid tumors beyond brain cancer, potentially expanding to other inoperable malignancies and inspiring drug-ultrasound combos.[1][3][6]
Alpheus Medical stands at a clinical inflection point, with Phase 1/2 success paving for a 2025 randomized trial in newly diagnosed GBM and potential expansion to other solid tumors.[5][6] Trends like AI-guided ultrasound refinement and combination therapies with immunotherapy will accelerate its path to pivotal data and FDA clearance, challenging standards like temozolomide.[4][5] Its influence could grow via nonprofit-backed scaling, positioning it as a leader in non-invasive oncology—if trial results hold. This biotech's targeted disruption echoes its founding promise: turning science fiction into feasible brain cancer care.[7]